Arca
Skip to content
Tools
Tools

IFNG: Interferon gamma

Type II interferon produced by immune cells such as T-cells and NK cells that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation.

  • Drugs that act on it: 3
  • Approved: 1
  • In phases 1 to 3: 2
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on IFNG, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 2
  • Other 1

Approved1

  • Emapalumab

Phase 30

    Phase 21

    • Fontolizumab

    Phase 11

    • AMG-811

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Interferon gamma inhibitor.
    EmapalumabApprovedNovImmuneAntibodyInhibitor16
    FontolizumabPhase 2PDL BioPharma, Inc.AntibodyInhibitor0
    AMG-811Phase 1AmgenOtherInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
    Severe Hepatitis Intervention With Emapalumab for Liver DiseaseEmapalumabPhase 2Not yet recruitingChildren's Healthcare of AtlantaAug 4, 2026
    Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANSEmapalumabPhase 2Not yet recruitingNYU Langone HealthMay 5, 2026
    Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft DysfunctionEmapalumabPhase 2Not yet recruitingUniversity of California, San FranciscoApr 20, 2026
    Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) StudyEmapalumabPhase 2RecruitingUniversity of MiamiMar 23, 2026
    Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell LymphomaEmapalumabPhase 4RecruitingThe First Affiliated Hospital of Soochow UniversityDec 8, 2025
    Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) RecipientsEmapalumabEarly phase 1RecruitingChildren's Hospital Medical Center, CincinnatiNov 24, 2025
    Randomized Stepped Wedge Study of Emapalumab in APECED EnteritisEmapalumabPhase 2RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)Oct 2, 2025
    Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell TransplantEmapalumabPhase 1RecruitingCity of Hope Medical CenterMay 30, 2025

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    Immunodeficiency 69
    0.51
    Primary hemophagocytic lymphohistiocytosis
    0.46
    Hemophagocytic syndrome
    0.39
    HIV-1 infection
    0.38
    Tuberous sclerosis
    0.38
    Macrophage activation syndrome
    0.35
    Hypothyroidism
    0.33
    Myxedema
    0.30
    Smoking initiation
    0.27

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3286073, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P01579, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.